FDA Regulatory Reversals Disrupt Drug Development Timelines for UniQure, Biohaven, and Capricor
核心洞察
Multiple biotechnology companies including UniQure, Biohaven (搜索), and Capricor have faced unexpected FDA reversals on previously agreed-upon evidence requirements for drug approvals since July 2024.
UniQure's Huntington's disease (搜索) gene therapy AMT-130, which showed 75% disease slowing in pivotal trials, had its biologics license application timeline thrown into uncertainty after FDA changed its stance on acceptable evidence.
The regulatory instability coincides with significant leadership changes at FDA, with the Center for Drug Evaluation and Research changing hands four times since early 2025 and philosophical differences emerging between current and previous FDA leadership.
Multiple biotechnology companies have encountered unexpected regulatory setbacks as the FDA has reversed previously agreed-upon evidence requirements for drug approvals, disrupting development timelines and forcing companies to reassess their strategies. The reversals have affected companies developing treatments for rare diseases with significant unmet medical needs.
UniQure's Huntington's Disease Setback
UniQure experienced one of the most dramatic reversals when the FDA changed its position on evidence requirements for AMT-130, a gene therapy for Huntington's disease (搜索). On September 24, the company was preparing to file a biologics license application in early 2026 based on three-year pivotal Phase I/II trial data showing 75% slowing of the neurodegenerative disease. The announcement sent UniQure's shares soaring 248%.
However, following a pre-BLA meeting in November, UniQure revealed that the FDA "no longer agrees" that the Phase I/II data would be "adequate to provide the primary evidence in support of a BLA submission." This represented what the company called a "key shift" from multiple Type B meetings held with the FDA over the past year, despite having aligned with the agency on protocols and statistical analyses, specifically comparing AMT-130 to a natural history external control.
The reversal has generated significant patient advocacy response, with more than 10,000 Huntington's patients, families and supporters signing petitions calling for FDA reconsideration. "For families who have long awaited new treatment options, the FDA's actions feel like a serious setback and have raised urgent concerns about transparency, consistency, and trust in the regulatory process," wrote Christina DeGryse, a Huntington's disease (搜索) advocate.
Biohaven's Spinocerebellar Ataxia Treatment Rejected
Biohaven (搜索) faced a similar reversal with troriluzole for spinocerebellar ataxia (搜索) (SCA), a genetic, inherited, life-threatening degenerative disease with no approved treatments. While the NDA was accepted in February, the treatment was rejected in November due to concerns about the company's real-world evidence study design.
In its complete response letter, the FDA cited "issues with Biohaven (搜索)'s Study 206-RWE that can be inherent to real-world evidence and external control studies, including potential bias, design flaws, lack of pre-specification and unmeasured confounding factors." The agency had previously communicated in March 2024 that "a large and robust treatment effect would be needed" to outweigh biases associated with real-world, externally controlled studies.
Biohaven (搜索) argued that data showing troriluzole slowed patients' decline by 50% to 70% versus untreated external comparators and delayed disease progression by 1.5 years to 2.2 years met this threshold. Following the rejection, Biohaven's stock dropped more than 40%, prompting the company to slash annual R&D spending by 60% and seek $150 million in funding.
Replimune's Melanoma Drug Rollercoaster
Cancer-focused Replimune experienced regulatory whiplash with its advanced melanoma (搜索) drug RP1. The company received a surprise rejection in July despite apparent FDA alignment on trial design. CEO Sushil Patel noted that "the issues highlighted in the CRL were not raised by the agency during the mid- and late-cycle reviews" and that the company "had also aligned on the design of the confirmatory study."
The rejection was later attributed to intervention by Oncology Center of Excellence director Richard Pazdur, who raised questions about RP1's efficacy after CBER allegedly mishandled the review. Following a September Type A meeting, Replimune announced that a path forward under accelerated approval "has not been determined," causing a nearly 40% stock crash. However, the FDA subsequently accepted a resubmission, sending shares soaring 93%.
Capricor's Early Warning Sign
San Diego-based Capricor may have been the first indicator of this trend when it received a complete response letter in July for deramiocel, a cell therapy for cardiomyopathy (搜索) associated with Duchenne muscular dystrophy (搜索). CEO Linda Marbán called the rejection "unexpected given the trajectory of positive interactions" with the FDA, stating the company "consistently met the agency's expectations throughout the review process."
Craig McDonald, director of the MDA Neuromuscular Disease Clinics at UC Davis and lead investigator on Capricor's trials, noted that "the previous leadership in the FDA really found the data quite compelling and encouraged the BLA submission."
Leadership Changes and Regulatory Philosophy Shifts
The regulatory instability coincides with significant leadership turnover at FDA. Since early 2025, the Center for Drug Evaluation and Research has changed hands four times, while the Center for Biologics Evaluation and Research has seen three different directors.
Graig Suvannavejh of Mizuho Securities attributed the regulatory variability to philosophical differences between current FDA leadership and previous directors like former CBER Director Peter Marks, "who has said to industry, 'We're flexible. We understand that there are areas of high medical need—patients need solutions, they need hope—and we're open for business.'"
Suvannavejh believes the current FDA still wants flexibility but may "dial up the criteria a bit more where you need to show a more compelling risk/reward profile."
BMO Capital Markets analyst Evan Seigerman described the current environment as creating "uncertainty" for biopharma companies, noting how companies can have "one set of guidance from FDA with regard to clinical trial design" only to experience "a 180" that "throws everything into a tailspin."
William Blair analysts questioned whether "the FDA is becoming more restrictive despite sponsors aligning on prior feedback," highlighting the broader implications for the biotechnology industry's relationship with regulatory authorities.